No abstract

No abstract

Twenty-one of 32 patients with locally advanced prostatic cancer (stage C) were treated with the LH-RH analogue Buserelin for 7-19 months. After an initial sequence of subcutaneous injections, treatment was continued with intranasal spray application (three daily doses of 400 micrograms each) which ensured maintenance of serum testosterone within the range seen in castrated men. To evaluate the response of the primary tumor to Buserelin, cytological regression was established for all patients by fine-needle aspiration biopsy every 3 months. The cytological results corresponded with those of DNA analyses of single-cell cytophotometry showing a statistically significant drop of the grade of aneuploidy or polyploidy when the prostatic carcinoma responded positively to Buserelin therapy. Seventeen of 21 patients treated with the potent LH-RH analogue showed good therapy response. Four patients with no cytological signs of tumor regression received secondary treatment with estramustine phosphate because of hormone resistence. One patient had to be crossed over to cyclophosphamide, the third drug, for clinical progression after 15 months. Essential side effects have not been observed. Continuous treatment of locally advanced prostatic cancer with Buserelin, combined with close control of the patient, offers not only a real alternative to surgical castration--as the patient is spared the psychical stress of orchiectomy--but also to estrogen therapy with its risk of cardiovascular side effects.

The results of this study suggest that DNA ploidy is a significant and independent predictor for survival of patients afflicted from RCC and superior to tumor classification and grade. DNA ploidy is a reliable prognostic factor for RCC and yields considerable information for patient management and predicting clinical outcome.

181 of 2,606 patients hospitalized for urolithiasis in 12 years were younger than 15 years (6.9 %). In accordance with the data given by other authors, we found the incidence of urolithiasis in children to be 1–5%, which, at least in Central Europe, corresponds approximately with that in adults. The causative factors or cofactors we established were malformation of the kidneys and urinary tract in 35.9%, and infections of the urinary tract in 80.7%. Defined metabolic disorders were found in only 5.5% of patients. Stone analysis showed a predominance of phosphate-containing calculi. Control examinations were done in 154 children over periods of 6 months to 11 years. ‘Recurrent lithiasis’ was seen in 32 patients, however, the exact comparison of pre- and postoperative X-ray films showed that in 17 cases the calculi had not been completely removed during surgery (11%). Consequently, a real recurrent lithiasis was present in 15 children only (9.9%). Since the West Berlin population includes a high percentage of Turkish people, we can conclude from our case material that even those Turkish children who were born in West Berlin suffer from urolithiasis 2–2.5 times as often as German children of the same age-groups.